Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.59 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733233 | 0.78 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL733237 | 0.78 | PIK3CG (0.51) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL15752919 | 0.77 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL735131 | 0.77 | PIK3CD (0.57) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL733544 | 0.76 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL733812 | 0.76 | PIK3CD (0.44) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL734097 | 0.76 | PIK3CG (0.51) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL734119 | 0.75 | PIK3CD (0.46) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL734766 | 0.75 | PIK3CG (0.61) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL27743792 | 0.75 | PIK3CD (0.46) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | PIK3CD 2843/4885PIK3R1 3357/4885PIK3CG 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.